Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Clinical Effect of the Combination Therapy of Hydroxychloroquine, Azithromycin and Ivermectin in Patients with COVID-19
Sathi et al., Journal of Cardiovascular Disease Research, doi:10.31838/jcdr.2021.12.05.11
Sathi et al., Clinical Effect of the Combination Therapy of Hydroxychloroquine, Azithromycin and Ivermectin in Patients with.., Journal of Cardiovascular Disease Research, doi:10.31838/jcdr.2021.12.05.11
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 85 COVID-19 patients including 8 ICU patients treated with ivermectin, HCQ, and AZ, showing all patients improving except for one patient that died 3 days after admission. Authors recommend early treatment. There was no control group.
Sathi et al., 31 Jul 2021, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Journal of Cardiovascular Disease Research ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021 Original Article Clinical Effect of the Combination Therapy of Hydroxychloroquine, Azithromycin and Ivermectin in Patients with COVID-19 SatyanandSathi1, Anil Kumar Garg 1, Amit Mittal2, Savita Verma* 4, Virendra Singh Saini1, Manoj Kumar Singh1, Devinder Vohra 1 , Sushil Kumar 3 1 Department of Medicine, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India Department of Community Medicine, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India 3 Department of Paediatrics,S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India 4 M.S. Obstetrics and Gynaecology, S.M.M.H. Government Medical College Saharanpur, Uttar Pradesh, India *Corresponding author: Dr. Savita Verma, Assistant Professor, M.S. Obstetrics and Gynaecology, S.M.M.H. Government Medical College, Ambala Road, Saharanpur, Uttar Pradesh, India, Email : Savita.sathi@gmail.com 2 Abstract Background: The ongoing pandemic has highlighted the need for an effective treatment of COVID-19 patients and prevention of SARS-CoV-2 community transmission.Methods: We conducted a prospective observational study on a cohort of 85 COVID-19 patients (80% males, median age 46 years, range 18–80 years). Patients were treated with a triple drug therapy: ivermectin 12 mg once a week, hydroxychloroquine 400 mg twice a day on the first day and 200 mg twice a day for the next 4 days, and azithromycin 500 mg once a day for 5 days. Endpoints were assessed by clinical outcomes, death, negative SARS-CoV-2 RNA-PCR test on the tenth day, and length of the hospital stay.Results: All patients improved except one 70-year-old female, who died on the third day of admission. The clinical outcome was considered good as 95.24% (80/84) of patients presented a negative SARS-CoV-2 RNA-PCR test on the tenth day of admission and 90.48% (76/84) were discharged in stable condition.Conclusions: The response must focus on immediate isolation of COVID-19 patients and their early treatment to prevent irreversible severe respiratory injury. Our study shows the beneficial effect of triple drug therapy in terms of clinical recovery, shorter duration of viral carriage, community spread prevention, and minimal cost of therapy. KeywordsHydroxychloroquine, Azithromycin, Ivermectin, COVID-19 patients
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit